A Prospective Observational Registry Study to Characterise Normal Conditions of Use, Dosing and Safety Following Administration of Vernakalant IV Sterile Concentrate
Phase of Trial: Phase IV
Latest Information Update: 03 Aug 2016
At a glance
- Drugs Vernakalant (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions
- Acronyms SPECTRUM
- Sponsors Cardiome Pharma
- 29 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2017.
- 29 Jul 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2017.
- 09 Oct 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.